A biotech emerges from one Deerfield's R&D donation partners
Two years ago, Deerfield began writing large checks to prestigious research institutes as part of a strategy to get in on the ground floor of top translational work. The close relationship they built with one of those institutes – Dana Farber – has now led to a new biotech.
Civetta Therapeutics announced $53 million in Series A funding to apply protein-protein interaction technology from the Dana Farber Cancer Institute and the Broad Institute to cancer and neurodegenerative diseases, among other targets. The scientific founders were Eric Fischer, head of the new Deerfield-endowed Center for Protein Degradation at Dana Farber, and William Sellers, who led oncology research at Novartis for 11 years before returning to Harvard and Dana-Farber. No investor besides Deerfield was named.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.